Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

Denise Yardley, MD
Published: Wednesday, Jan 15, 2020



Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Currently, CDK4/6 inhibitors are a standard first- or second-line treatment for patients with HR–positive, HER2-negative breast cancer, says Yardley.

Initially, there was a learning curve with the use of these agents, particularly for patients who have a high tumor burden or metastases in the liver or lung.

However, studies have demonstrated an improvement in overall response rates, progression-free survival, and overall survival with CDK4/6 inhibitors versus standard chemotherapy, says Yardley.

Moving forward, it will be important to understand resistance mechanisms and identify patients who are likely to respond to CDK4/6 inhibitors versus chemotherapy, concludes Yardley.
SELECTED
LANGUAGE


Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Currently, CDK4/6 inhibitors are a standard first- or second-line treatment for patients with HR–positive, HER2-negative breast cancer, says Yardley.

Initially, there was a learning curve with the use of these agents, particularly for patients who have a high tumor burden or metastases in the liver or lung.

However, studies have demonstrated an improvement in overall response rates, progression-free survival, and overall survival with CDK4/6 inhibitors versus standard chemotherapy, says Yardley.

Moving forward, it will be important to understand resistance mechanisms and identify patients who are likely to respond to CDK4/6 inhibitors versus chemotherapy, concludes Yardley.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x